A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer by Samardzija, Chantel et al.
  
 
 
 
Samardzija, Chantel, Luwor, Rodney B., Volchek, Mila, Quinn, Michael A., Findlay, Jock K. and Ahmed, 
Nuzhat 2015, A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse 
model of ovarian cancer, Molecular cancer, vol. 14, no. 152, pp. 1-19. 
 
DOI: 10.1186/s12943-015-0417-y 
 
 
 
 
 
 
 
 
This is the published version. 
 
© 2015, The Authors 
 
Reproduced by Deakin University under the terms of the Creative Commons Attribution Licence 
 
 
 
 
 
 
 
 
 
 
 
Available from Deakin Research Online: 
 
http://hdl.handle.net/10536/DRO/DU:30093727 
 
 
 
 
 
Samardzija et al. Molecular Cancer  (2015) 14:152 
DOI 10.1186/s12943-015-0417-yRESEARCH Open AccessA critical role of Oct4A in mediating
metastasis and disease-free survival in a
mouse model of ovarian cancer
Chantel Samardzija1,2, Rodney B Luwor3, Mila Volchek4, Michael A Quinn1,2, Jock K Findlay1,2,5
and Nuzhat Ahmed1,2,5,6,7*Abstract
Background: High grade epithelial ovarian cancer (EOC) is commonly characterised by widespread peritoneal
dissemination and ascites. Metastatic EOC tumour cells can attach directly to neighbouring organs or alternatively,
maintain long term tumourigenicity and chemoresistance by forming cellular aggregates (spheroids). Cancer stem-like
cells are proposed to facilitate this mechanism. This study aimed to investigate the role of Oct4A, an embryonic stem
cell factor and known master regulator of pluripotency in EOC progression, metastasis and chemoresistance.
Methods: To investigate the expression of Oct4A in primary EOC tumours, IHC and qRT-PCR analyses were used. The
expression of Oct4A in chemonaive and recurrent EOC patient ascites-derived tumour cells samples was investigated
by qRT-PCR. The functional role of Oct4A in EOC was evaluated by generating stable knockdown Oct4A clones in the
established EOC cell line HEY using shRNA-mediated silencing technology. Cellular proliferation, spheroid forming
ability, migration and chemosensitivty following loss of Oct4A in HEY cells was measured by in vitro functional assays.
These observations were further validated in an in vivo mouse model using intraperitoneal (IP) injection of established
Oct4A KD clones into Balb/c nu/nu mice.
Results: We demonstrate that, compared to normal ovaries Oct4A expression significantly increases with tumour
dedifferentiation. Oct4A expression was also significantly high in the ascites-derived tumour cells of recurrent EOC
patients compared to chemonaive patients. Silencing of Oct4A in HEY cells resulted in decreased cellular proliferation,
migration, spheroid formation and increased chemosensitivity to cisplatin in vitro. IP injection of Oct4A knockdown
cells in vivo produced significantly reduced tumour burden, tumour size and invasiveness in mice, which overall
resulted in significantly increased mouse survival rates compared to mice injected with control cells.
Conclusions: This data highlights a crucial role for Oct4A in the progression and metastasis of EOC. Targeting Oct4A
may prove to be an effective strategy in the treatment and management of epithelial ovarian tumours.
Keywords: Ovarian carcinoma, Cancer stem cells, Metastasis, Ascites, Chemoresistance, Recurrence, Oct4AIntroduction
Epithelial ovarian cancer (EOC) remains the most preva-
lent of all the gynaecological malignancies with approxi-
mately 250,000 women diagnosed worldwide with the
disease each year [1]. Despite extensive treatment regi-
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this article, unless otherwise stated.the disease carries a poor prognosis with a 5 year mortality
rate greater than 70 % [2]. This is predominately due to
exceptionally high rates of disease recurrences driven by
widespread peritoneal metastasis and ascites [3]. Although
the metastasis of EOC is a highly complex and multi-stage
process [4], it is further emphasised by the lack of anatom-
ical barriers within the pelvic cavity. Consequently, malig-
nant tumour cells from the primary ovarian site are freely
able to exfoliate directly into the peritoneal cavity. Here
they directly attach to the mesothelial lining of the periton-
eum before invading adjacent pelvic organs including therticle is distributed under the terms of the Creative Commons Attribution
mons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
you give appropriate credit to the original author(s) and the source,
ense, and indicate if changes were made. The Creative Commons Public
ommons.org/publicdomain/zero/1.0/) applies to the data made available in
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cells can also maintain long term tumourigenicity within
the peritoneal cavity by forming non-adherent multicellular
tumour aggregates (spheroids) in the ascites micro-
environment [5]. This combined with the emergence of
drug resistant tumour cells following extensive chemo-
therapy regimens presents a major challenge in the
management of the disease [6, 7]. In order to reduce re-
current EOC tumour burden and improve overall patient
survival rates, the molecular mechanisms involved in
ascites-mediated EOC progression must be investigated.
Recent evidence suggests solid tumours including those
of ovarian origin contain a sub-population of tumour cells
exhibiting unlimited self-renewal and pluripotent abilities
[8]. These cells, termed cancer stem cells (CSCs) have
gained considerable momentum in cancer biology over
the past decade and are hypothesized to mediate tumour
cell survival [9], sustain cytotoxic pressure [10, 11] and
initiate metastatic recurrence [12]. Indeed, we and others
have shown recurrent chemoresistant ovarian tumour
cells to be enriched in CSC-like cells and stem cell path-
way mediators, indicating that CSCs may contribute to
the progression of disease [13–17]. Overall, this suggests
that targeting CSCs may provide an effective and accurate
method of treating recurrent EOC disease [18–20]. It is
therefore vital that tumour specific CSCs as well as the
pathways regulating their survival are identified and
explored.
Oct4 (Oct3/4 or POU5F1), an embryonic stem cell factor
and member of the POU family of transcription factors, has
been extensively studied in solid tumours including those
of the lung [21], brain [22], and breast [23] where it has
closely been related to tumour progression [24], self-
renewal [25] and drug resistance [26]. In developmental
biology, it is known to play a pivotal role for the mainten-
ance of totipotency in primary blastomeres and pluripo-
tency of the inner cell mass of developing mammalian
embryos [27, 28]. While up regulation of Oct4 sustains an
undifferentiated pluripotent stem cell state, a loss of Oct4
induces stem cells to undergo differentiation, producing a
heterogeneous population of highly specialized daughter
cells [29]. Unfortunately, several studies previously investi-
gating Oct4 in relation to tumour progression and che-
moresistance have failed to recognize the several Oct4
isoforms generated by alternative splicing [30] termed
Oct4A, Oct4B and Oct4B1. Of these isoforms, only the
nuclear-specific Oct4A isoform is known to be capable of
regulating the pluripotent nature of stem cells [31, 32]. This
along with the several known pseudogenes [33], makes in-
vestigating and interpreting the current literature on Oct4
complex. Hence, to elucidate the expression and the bio-
logical functions of Oct4 in the context of cancer stem cells,
it is important to discriminate between the several isoforms
and pseudogenes of Oct4.In this study, for the first time using Oct4A specific
antibody and primers we determined the expression of
Oct4A in a range of serous ovarian tumours of different
histological grades, and in tumour cells isolated from the
ascites of recurrent and chemonaive EOC patients. Our
results reveal that the expression of Oct4A significantly
correlated to serous ovarian tumour dedifferentiation
and was significantly elevated in the isolated tumour
cells of chemotherapy treated recurrent patients com-
pared to untreated chemonaive patients. Using a highly
aggressive and metastatic ovarian cancer cell line (HEY)
which sustains high endogenous expression of Oct4A,
we show that suppression of Oct4A resulted in the loss
of CSC-associated expression of Lin28, Sox-2, EpCAM
and CD44. This was associated with a decrease in cellu-
lar proliferation, migration, spheroid forming abilities
and resulted in enhanced sensitivity to cisplatin in vitro.
These results correlated with those obtained from
in vivo mouse xenograft studies. Mice transplanted with
Oct4A knockdown cells demonstrated significantly re-
duced tumour burden and abrogation of tumour invasive
ability, which overall resulted in significantly increased
survival rates compared to mice injected with vector con-
trol cells. These data emphasize the need to explore fur-
ther the effect of Oct4A expression in pre-clinical ovarian
cancer models.
Results
Oct4A is over expressed in primary serous ovarian
carcinomas and in the ascites-derived isolated tumour
cells of recurrent patients
To first establish whether Oct4A is expressed in primary
serous ovarian tumours, a total of 26 paraffin embedded
cases (Table 1), consisting of 6 normal ovarian epithelia,
5 well differentiated borderline serous tumours, 7 mod-
erately differentiated grade 2 serous tumours, and 8
poorly differentiated grade 3 serous tumours were ana-
lysed by immunohistochemistry using a human Oct4A-
specific antibody specifically targeting the N-terminal of
the Oct4 protein. Enhanced expression of Oct4A was ob-
served in ovarian tumours compared to normal ovarian
epithelium samples (Fig. 1a & Additional file 1: Figure S1).
This expression was noted in both the cytoplasm and nu-
clei of tumour cells, with a greater number of nuclear
staining observed in grade 2 and grade 3 tumours com-
pared to normal and borderline specimens. However, a
small section of ovarian surface epithelium stained posi-
tive for Oct4A. It is not certain whether this is true Oct4A
staining or simply an ‘edging effect’. A significant differ-
ence in Oct4A staining (both cytoplasmic and nuclear)
was however observed between all serous tumour samples
and normal ovarian tissues (Fig. 1b) with weak Oct4A
staining observed in normal ovarian epithelium tissue
samples (DAB reading: 2.75 ± 0.76), moderate staining in
Table 1 Description of patient samples used for IHC analysis
Sample no. Diagnosis FIGO stage Age Pre-operative CA125 Survival
Normal
1 Normal ovarian epithelium - NA - -
2 Normal ovarian epithelium - 61 - -
3 Normal ovarian epithelium - 69 - -
4 Normal ovarian epithelium - 65 - -
5 Normal ovarian epithelium - 62 - -
6 Normal ovarian epithelium - NA - -
Borderline
1 Serous cystadenocarcinoma Ib 50 12 4 years 10 months ALC
2 Serous cystadenocarcinoma Ic 31 117 4 years 9 monthsa
3 Serous cystadenoma Ia 60 1237 5 years ALC
4 Serous cystadenoma Ic 32 34 4 years 8 monthsa
5 Papillary serous cystadenocarcinoma Ia 47 NA 5 years 8 months ALC
Grade 2
1 Papillary serous cystadenocarcinoma IIIc 71 NA 8 months ALC
2 Papillary serous cystadenocarcinoma IIIc 43 428 3 years 7 months until death
3 Papillary serous cystadenocarcinoma IIIc 52 309 10 months ALC
4 Papillary serous cystadenocarcinoma IV 58 3187 6 years 1 months ALC
5 Papillary serous cystadenocarcinoma IIIc 41 NA 8 years 8 monthsa
6 Serous cystadenoma NOS IIIc 49 463 2 years 7 monthsa
7 Serous cystadenoma NOS IIIa 64 1404 7 months ALC
Grade 3
1 Papillary serous cystadenoma IIIc 75 1443 4 yrsa
2 Papillary serous cystadenocarcinoma IIc 67 24 2 months ALC
3 Serous cystadenocarcinoma NOS IIIc 55 3025 2 years 5 months until death
4 Serous cystadenocarcinoma NOS IIIc 59 4224 1 year 4 months until death
5 Serous cystadenocarcinoma NOS IIIc 76 130 3 years 6 monthsa
6 Serous cystadenocarcinoma NOS IIc 60 107 3 years 6 monthsa
7 Serous cystadenocarcinoma NOS IIIc 42 264 10 months until death
8 Serous cystadenocarcinoma NOS IIIc 58 490 2 years 8 monthsa
NOS Not Otherwise Specified, ALC At Last Contact
aindicates patients were alive at the time of manuscript preparation
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mours and moderate to high in and grade 3 tumours
(7.28 ± 0.72). Real-time PCR analysis using a primer
set specifically targeting exon 1 of the Oct4 gene also
confirmed significantly increased expression of Oct4A
at the mRNA level with 50 % of poorly differentiated
grade 3 serous tumour samples exhibiting moderate to
high expression of Oct4A compared to normal ovarian
samples (Fig. 1c) (Table 2).
To determine whether Oct4A may play a role in the che-
moresistant nature exhibited by recurrent EOC tumour
cells, we next examined the expression Oct4A in isolated
tumour cells derived from the ascites of chemonaïve and
recurrent patients (Table 3.3). Oct4A mRNA expressionwas significantly elevated in tumour cells derived from the
ascites of recurrent patients compared to those derived
from untreated chemonaive patients (Fig. 1d) (Table 3).
Oct4A is over expressed in human ovarian cancer cell
lines OVCAR5, SKOV3 and HEY
To further examine the expression of Oct4A in EOC, the
endogenous expression of Oct4A in the established EOC
cell lines OVCAR5, SKOV3, OVCA433 and HEY was in-
vestigated by real-time PCR analysis. When compared to
normal ovarian surface epithelium cell line ISOE398, the
results demonstrated that all cell lines with the exception of
OVCA433 displayed significantly increased expression of
Oct4A compared to ISOE398 cell line (Fig. 2a). It was also
Fig. 1 Expression and localization of Oct4A in primary serous epithelial ovarian tumours. a Representative immunohistochemical staining of
Oct4A in normal (n = 7), borderline (n = 5), grade 2 (n = 7) and grade 3 (n = 8) primary ovarian tumours. Positive Oct4A expression is indicated by
intense nuclear staining. Images are set at 200x (top panels including negative controls) and 400x (bottom panels). Scale bars represent 10 μM. b
Quantification of Oct4A staining using Image J software which recognizes total DAB intensity. Variations in staining were determined by
subtracting the negative control DAB reading from the Oct4A DAB reading for each tissue sample. Data is presented as the mean ± SEM of Oct4A
DAB staining intensity. Significance is indicated by *P < 0.05, **P < 0.01 or ***P < 0.001 as determined by One-way ANOVA using Dunnett’s Multiple
Comparison post-test compared to normal ovarian epithelium tissue. c Oct4A mRNA expression in primary normal ovarian epithelium tissues (n = 6)
and primary Grade 3 serous epithelial ovarian tumours (n = 11) was determined by qPCR analysis. Relative quantification of Oct4A mRNA expression is
standardized to 18S housekeeping gene and normalized to normal ovarian epithelium tissues. Data is expressed as the mean ± SEM of log2 transformed
data of samples performed in triplicate. Significant increase of Oct4A expression in Grade 3 serous EOC tumours is indicated by *P< 0.05 as determined by
student's t-test. d qPCR analysis of Oct4A expression in tumour cells isolated from the ascites of chemonaive (n = 6) and recurrent (n = 6) serous EOC
patients. Relative quantification of Oct4A mRNA expression was standardized to 18S housekeeping gene. Data is expressed as the mean ± SEM of
Oct4A mRNA expression of each sample performed in triplicate. Significance is indicated by *P < 0.05 as determined by student's t-test
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cell line expressed the greatest endogenous level of Oct4A
with an 8-fold increase in Oct4A expression compared to
ISOE398 cell line, and an overall 2-fold increase compared
to other ovarian cancer cell lines.Efficient shRNA mediated knockdown of Oct4A in HEY
epithelial ovarian cancer cell line
To determine the potential biological role of Oct4A in
ovarian carcinomas, loss of function studies were per-
formed in Oct4A expression abundant HEY cell line
Table 2 Description of patient tissue samples used for quantitative Real-Time PCR analysis
Sample no. Diagnosis FIGO stage Age Pre-operative CA125 Survival
Normal
1 Normal ovarian epithelium - NA - -
2 Normal ovarian epithelium - 62 - -
3 Normal ovarian epithelium - 45 - -
4 Normal ovarian epithelium - 57 - -
5 Normal ovarian epithelium - 36 - -
Grade 3
1 Serous cystadenocarcinoma NOS IIIc 55 3025 2 years 5 months until death
2 Serous cystadenocarcinoma NOS IIc 56 1447 5 years 1 monthsa
3 Papillary serous cystadenocarcinoma IIIc 75 4831 4 years 1mth until death
4 Serous cystadenocarcinoma NOS IV 50 7190 1 year 10mtha
5 Serous cystadenocarcinoma NOS IIIc 59 4224 1 year 4 months until death
6 Serous cystadenocarcinoma NOS IIIc 76 130 3 years 6 monthsa
7 Serous cystadenocarcinoma NOS IIIc 38 957 2 years 2 monthsa
8 Serous surface papillary carcinoma IIIc 59 397 4 years 7 months until death
9 Papillary serous cystadenocarinoma IIIc 64 485 1 year 6 months until death
10 Papillary serous cystadenocarinoma IIc 68 1934 4 years 9 monthsa
11 Serous cystadenocarcinoma NOS IIIc 70 459 2 years 5 months until death
NOS Not Otherwise Specified
aindicates patients were alive at the time of manuscript preparation
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cells were transfected with either the shRNA vector con-
trol plasmid or the Oct4A targeting shRNA plasmid.
Several Oct4A knockdown (KD) clones were produced
and evaluated for Oct4A silencing by real-time PCR ana-
lysis. Of these, knockdown clones 1&2 (HEY Oct4A
KD1 and HEY Oct4A KD2) showed significant suppres-
sion of Oct4A mRNA compared to HEY vector control
cells with a knockdown efficiency of 80-90 % (Fig. 2b).
Oct4A knockdown was seen to be less effective at the
protein level with Western blot analysis on nuclear cell
lysates suggesting a 40-50 % decrease in Oct4A expres-
sion in HEY Oct4A KD1 and Oct4A KD2 cells com-
pared to vector control cells (Figs. 2c & d). As expected
there were no differences in the expression of Oct4A
mRNA or protein expression in vector control cells when
compared to parental cells. Morphologically, the loss of
Oct4A expression had no effect on HEY cells (Fig. 2e).
Knockdown of Oct4A suppressed the expression of Lin28
and Sox2 in monolayer HEY cultures
To investigate whether loss of Oct4A had any effect on
the expression of other Oct4-associated genes, we ana-
lyzed the expression of embryonic stem cell markers
Lin28 and Sox2 in Oct4A KD cells by real-time PCR
analysis. The mRNA levels of both Lin28 and Sox2 were
suppressed in Oct4A KD cells by >50 % when compared
to vector control cells (Figs. 2 f & g). This was furtherconfirmed at the protein level by Western blot analysis
(Figs. 2h & i).
Knockdown of Oct4A altered the spheroid forming ability
of HEY cells and suppressed the expression of Lin28 and
Sox2 in non-adherent spheroid cultures
The ability of tumour cells to form anchorage-independent
multicellular aggregates within ascites fluid plays a crucial
role in the survival and metastasis of epithelial ovarian tu-
mours [34, 35]. To examine the effects of Oct4A knock-
down on the ability of HEY cells to form spheroids, vector
control, Oct4A KD1 and Oct4A KD2 cells were cultured
on ultra-low attachment plates and monitored over 18 days
(Fig. 3a). Vector control cells formed large, compact spher-
oids with a notable outer rim and were capable of main-
taining their integrity within 18 days in culture. In
comparison, the ability of both Oct4A KD1 and Oct4A
KD2 cells to form spheroids was almost completely abro-
gated, with both Oct4A KD clones forming smaller and
irregular-shaped spheroids which appeared to disintegrate
in culture. When assessed at 18 days, the number of spher-
oids (>200 μM) produced by Oct4A KD1 and Oct4A KD2
cells was significantly reduced (50-80 %) when compared to
spheroids produced by vector control cells (Fig. 3b).
Since the formation of multicellular spheroids within
ascites fluid has previously been reported to be essential
in the preservation and survival of ovarian CSCs [36],
the expression of Oct4A, along with Lin28 and Sox2 was
Table 3 Description of patient ascites samples used for quantitative Real-Time PCR analysis
Sample no. Diagnosis Silverberg
grade
FIGO
stage
Treatment Age Survival
Chemonaive
1 Serous Cystadenoma/ Early
Serous Borderline
NA NA None 64 NA
2 Serous Cystadenocarcinoma NA III None 65 1 year 5 monthsa
3 Serous Papillary Carcinoma G3 NA None NA NA
4 Papillary Serous
Cystadenocarcinoma
G3 IIIc None 48 1 year 6 monthsa
5 Serous Cystadenocarcinoma
NOS
G3 IIIa None 51 1 year 3 monthsa
6 Serous Cystadenocarcinoma
NOS
G3 NA None 71 1 year 1 montha
Recurrent
1 Serous Cystadenocarcinoma
NOS
G3 IIc Carboplatin and Paclitaxel 2 Cycles 64 5 months until
death
2 Adenocarcinoma NOS NA IV Carboplatin and Paclitaxel 6 Cycles 67 2 years 8 months
until death
3 Serous Cystadenocarcinoma
NOS
G3 IIIc Carboplatin/Paclitaxel/ Bevacizumab-VGEF Inhibitor
(ICON7 Trial) 18 Cycles
55 5 years 6 months
until death
4 Papillary Serous
Cystadenocarcinoma
G3 IIIc Carboplatin and Paclitaxel 6 Cycles 59 3 years 2 months
until death
Gemicitabine and Cisplatin
5 Papillary Serous
Cystadenocarcinoma
G3 IIIc Carboplatin/Paclitaxel/BIBF1120- Angiogenesis
Inhibitor (OVAR12 Study)
46 3 years 11 months
ALC
6 Serous Cystadenocarcinoma
NOS
G3 IV Bevacizumab 1 cycle 57 4 years 3 months
Paclitaxel and Cisplatin 6 cycles ALC
Doxorubicin Pegylated Liposomal 6 cycles
NOS Not Otherwise Specified, ALC At Last Contact
aindicates patients were alive at the time of manuscript preparation
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trol and Oct4A KD cells by quantitative real-time PCR
analysis (Fig. 3c). Consistent with monolayer cultures,
the mRNA expression of Oct4A, Lin28 and Sox2 were
significantly reduced in Oct4A KD spheroids (40-70 %)
compared to vector control spheroids (Fig. 3c).
Knockdown of Oct4A reduced the ability of knockdown
cell spheroids to adhere to plastic and suppressed the
expression of cancer stem cell glycoproteins EpCAM and
CD44 in monolayer cultures
The ability of ascites tumour spheroids to colonize and
invade at distant sites is crucial for the survival and me-
tastasis of EOC tumours [37, 38]. To determine if loss of
Oct4A expression in HEY cells reduces the ability of
spheroids to adhere to plastic, 24 h colony forming as-
says were performed on 18 day vector control and
Oct4A KD spheroids. Compared to vector control spher-
oids, a significantly reduced number of Oct4A KD1 and
Oct4A KD2 spheroids were capable of adhering to plas-
tic within 24 h (Figs. 4a & b). Furthermore, microscopic
analysis of adhered spheroids revealed cells within vector
control spheroids were capable of effectively migratingaway from the adhered spheroid core. Conversely, cells
from adhered spheroids produced by Oct4A KD cells ex-
hibited little to no cellular migration away from the
spheroid core (Fig. 4a).
A change in the ability of HEY cells to form tightly
compacted spheroids with reduced adhesive abilities sug-
gests alterations in the expression of adhesive proteins
may also be effected following loss of Oct4A expression.
EpCAM and CD44 are oncogenic glycoproteins com-
monly expressed by EOC solid tumours and ascites
tumour cells [14, 39]. Additionally, both have been associ-
ated with a CSC-like phenotype [40, 41]. When compared
to vector control cells, a significant loss of EpCAM
(>70 %) and CD44 (>60 %) mRNA expression was ob-
served in Oct4A KD monolayer cultures (Fig. 4c).
Suppression of Oct4A inhibited migratory ability of HEY
cells in vitro
Motility remains an important parameter in tumour me-
tastasis and reflects the ability of tumour cells to migrate
away from the original site into neighbouring tissues and
distant metastasised sites [42]. To determine whether
loss of Oct4A affects the migratory ability of HEY cells,
Fig. 2 Stable shRNA knockdown of Oct4A in epithelial ovarian cancer cell line HEY. a Four established epithelial ovarian cancer cell lines OVCAR5,
SKOV3 OVCAR433 and HEY were screened for endogenous expression of Oct4A mRNA by qPCR analysis. Relative quantification of Oct4A mRNA
expression was standardized to 18S housekeeping gene and normalized to the normal ovarian epithelium immortalized cell line ISOE398. b
shRNA-mediated silencing of Oct4A in HEY cells (Oct4A KD1 and Oct4A KD2) was confirmed by qPCR analysis. Relative Oct4A levels were normalized
to 18S housekeeping gene and calibrated to vector control samples prepared in triplicate. c Western blot analysis using nuclear cell lysates and 12 %
SDS-PAGE gels further validating Oct4A knockdown in Oct4A KD cells as determined by protein bands present at ~50 kDa. Total protein load
was determined by stripping and re-probing the membrane with GAPDH. d Oct4A protein expression was significantly reduced in Oct4A KD
cells as determined by densitometry analysis. Data is expressed as a ratio of Oct4A protein expression compared to GAPDH protein expression.
e Phase contrast images of exponentially growing HEY cells cultured on plastic indicating no obvious morphological changes following
shRNA-mediated knockdown of Oct4A. Magnification is set at 100x. Scale bar represents 50 μM. f-g Lin28 and Sox2 mRNA expression was
investigated by qPCR analysis. Relative Lin28 and Sox2 levels were normalized to 18S housekeeping gene and calibrated to vector control
samples prepared in triplicate. h-i Lin28 and Sox2 protein expression in Oct4A KD cells was investigated by Western blot analysis. Cytoplasmic
cell lysates were prepared for Lin28 analysis and nuclear cell lysates used for Sox2 analysis. Total protein load was determined by stripping
and re-probing the membrane with GAPDH. For all graphs sets, data is expressed as the mean fold change ± SEM from three independent
samples. Significance is indicated by *p < 0.05, **p < 0.01 and ***p < 0.001 and determined by One-Way ANOVA using Dunnett's post-test
compared to the ISOE398 cell line or HEY vector control
Samardzija et al. Molecular Cancer  (2015) 14:152 Page 7 of 1924 h wound healing assays were performed (Fig. 5a).
Suppression of Oct4A in HEY cells had a significant im-
pact on the migration of HEY cells with Oct4A KD cellsexhibiting ~50 % reduction in migratory ability com-
pared to vector control cells (Fig. 5b). This was consist-
ent with significantly reduced (~50 %) mRNA expression
Fig. 3 Suppression of Oct4A resulted in reduced spheroid forming ability and a loss of Lin28 and Sox2 in HEY cells. a The spheroid forming
ability of HEY cells following stable shRNA-mediated knockdown of Oct4A was assessed by culturing cells on ultra-low attachment plates as described
in the Materials and Methods. Cellular aggregation was monitored over 18 days and documented using phase contrast microscopy. Images
are representative of three independent experiments set at 100x magnification. Scale bar represents 100 μM. b The number of spheroids produced
after 18 days was assessed using a phase contrast microscope calibrated with an ocular micrometer. Spheroids with a diameter greater than 200 μM
were classified as spheroids. c Expression of Oct4A, Lin28 and Sox2 in Oct4A KD 18 day spheroids was evaluated by qPCR analysis. Relative quantification
of Oct4A, Lin28 and Sox2 mRNA expression in Oct4A knockdown cells was standardized to 18S housekeeping gene and normalized to vector control cells
Samardzija et al. Molecular Cancer  (2015) 14:152 Page 8 of 19of MMP2 in Oct4A KD cells compared to vector control
cells (Fig. 5c).
HEY cells exhibited reduced proliferative rates following
shRNA-mediated knockdown of Oct4A
Cellular proliferation is fundamental in the survival of
tumour cells and in the overall maintenance of a solid
tumour mass [43]. Since Oct4A is well known for regu-
lating self-renewal and survival in ESCs [31], the prolif-
erative ability of HEY cells following shRNA-mediated
knockdown of Oct4A was investigated using 72 h MTT
cell viability assays (Fig. 5d). When compared to vector
control cells, both Oct4A KD1 and Oct4A KD2 cells
demonstrated significant decrease in cellular prolifera-
tion 72 h post plating (30 & 50 % respectively) (Fig. 5d).
Loss of Oct4A expression enhanced HEY cell sensitivity to
cisplatin treatment
As discussed previously, chemotherapeutic resistance
has been shown to be attributed by CSCs [13, 15, 44].
To determine whether Oct4A plays a role in chemother-
apy induced drug resistance in EOC, the expression ofOct4A was investigated in ovarian cancer cell lines
treated with cisplatin for 72 h. Consistent with the pro-
file generated by recurrent chemotherapy treated patient
ascites samples, Oct4A mRNA levels were found to be
significantly elevated in all cell lines following cisplatin
treatment when compared to their untreated control
counterparts (Fig. 5e). This elevation suggests a possible
role of Oct4A in mediating drug resistance in EOC. The
sensitivity of HEY cells to cisplatin following loss of
Oct4A was investigated. Compared to cisplatin treated
vector control cells, both Oct4A KD1 and Oct4A KD2
cells showed significant increase in sensitivity to 72 h
cisplatin treatment as indicated by a decrease in the GI50
value (Fig 5f). Overall, vector control cells exhibited a cis-
platin GI50 value of ~2 μg/ml compared to ~1-1.5 μg/ml
for Oct4A KD cells.
Suppression of Oct4A in HEY cells reduced tumour
burden and prolonged survival of mice in xenograft
models
To further investigate the role of Oct4A in EOC pro-
gression in vivo intraperitoneal (ip) HEY xenograft
Fig. 4 Loss of Oct4A expression resulted in reduced adhesion abilities of spheroids and colony formation in HEY cells. a Vector control and Oct4A
KD cells were grown as non-adherent spheroids cultures on ultra-low attachment plates as described in the Material and Methods. Following
18 day incubation, spheroids were transferred to 6 well plastic culture plates and incubated for 24 h. Adhered spheroids were then fixed with formalin
and stained with 5 % crystal violet. All images are representative of three independent experiments performed in duplicate. Magnification 100x and
scale = 100 μM b Colony formation in 18 day Oct4A KD spheroids was significantly reduced when compared to vector control spheroids. c Expression
of adhesion markers CD44 and EpCAM in monolayer Oct4A KD cells was determined by qPCR analysis. Relative quantification CD44 and EpCAM mRNA
expression in Oct4A KD cells were standardized to 18S housekeeping gene and normalized to the vector control. All data sets are presented as the
mean ± SEM of three independent experiments as determined by One-Way ANOVA and Dunnett's Multiple Comparison post-test compared to vector
control. Significance is indicated by *P < 0.05, **p < 0.01 and ***P < 0.001
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previously [15]. 4 weeks post inoculation, mice injected
with vector control cells displayed several characteristics
of advanced stage metastatic disease including abdom-
inal swelling and weight loss (Fig. 6a). Dissection of theabdominal cavity revealed the formation of multiple
macroscopic disease deposits primarily visible on the
liver, pancreas, large and small bowels. Several smaller
tumour nodules were also seeded throughout the entire
peritoneal cavity. In comparison, mice injected with
Fig. 5 Loss of Oct4A reduced migratory and proliferative abilities in HEY cells while increasing chemosensitivity to cisplatin treatment. a The
migratory ability of Oct4A KD cells was determined by 24 h wound healing assay. Cells were grown as confluent monolayer prior to the insertion
of a single wound and allowed to migrate for 24 h. Images of the wounds were taken at t = 0 h and t = 24 h post wound insertion and are
representative of three independent experiments. Images are at 100x magnification and scale bar represents 50 μM. b 24 h migration expressed
as a percentage of wound closure compared to t = 0 h using an ocular micrometer. Data is presented as the mean ± SEM of three independent
experiments. Significance is indicated by **p < 0.01 as determined by One-Way ANOVA compared to vector control. c qPCR analysis of MMP2
mRNA expression in Oct4A KD monolayer cells. Relative quantification of MMP2 mRNA expression in Oct4A knockdown cells was standardized to
18S housekeeping gene and normalized the vector control. d Proliferative potential of Oct4A KD cells was determined by MTT assay over a 72 h
period. Proliferation rates are expressed as the percentage of cell growth compared to 24 h. Data is presented as the mean ± SEM of three individual
experiments performed with 6 replicates. Significance at t = 72 h is indicated by *p < 0.05 and ***p < 0.001 as determined by Two-way
ANOVA compared to HEY Vector Control. e mRNA expression of Oct4A in ovarian cancer cell lines following cisplatin treatment. Relative quantification
of Oct4A mRNA expression in ovarian cancer cells was standardized to 18S housekeeping gene and normalized to untreated controls for each cell line.
Data is presented as the mean ± SEM of three independent experiments. Significance is indicated by ***p < 0.001, **p < 0.01 and *p < 0.05 compared
to the respected untreated control for each cell line as determined by student's test. f Loss of Oct4A increased HEY cell sensitivity to 3 day cisplatin
treatment as determined by MTT assay. Data is presented as the mean ± SEM of three independent experiments performed in triplicate and expressed as
a percentage of cell survival compared to untreated cells for each group. Significance is indicated by *p< 0.05 and ***p< 0.001 for both Oct4A KD1 and
Oct4A KD2 at 1 μg/ml and 2 μg/ml as determined by Two-way ANOVA compared to vector control cells
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ill health and displayed no evidence of tumour formation
4 weeks post inoculation. Only after surgical dissection
was it evident that mice injected with Oct4A KD cells
produced significantly smaller tumours and an overall
reduced tumour burden (Figs. 6a & b). Despite obvious
growth reductions, histological examination of excised
xenograft tumours revealed that Oct4A KD cells-derived
tumours retained similar morphology to that producedby vector control cells (Fig. 6a). Further microscopic in-
vestigation revealed however, that tumours derived from
Oct4A KD cells exhibited a higher cytoplasm/nucleus
ratio compared to those produced by HEY vector con-
trol cells (Fig. 6c).
Since, the majority of mice injected with Oct4A KD
cells displayed little to no tumour development at
4 weeks, the survival rates of mice injected with Oct4A
KD1 and KD2 cells was assessed over a 6 months period
Fig. 6 In vivo tumour development in mice injected with HEY Oct4A knockdown cells. a 5 × 106 vector control, Oct4A KD1 and Oct4A KD2 HEY
cells were inoculated by ip injection into 6–8 week old female BALB/c nu/nu mice (n = 11/group). 4 weeks post injection tumour development
was photographed, mice euthanized and b tumour burden calculated. Oct4A KD cells exhibited significantly decreased tumour formation as
determined by One Way ANOVA and Turkey’s post-test. Significance is indicated by ***p < 0.001. c Excised tumours were subjected to H&E staining.
Images are set at 200x magnification and are representative of n = 4 per group. Scale bar is set at 50 μM. d Prolonged survival status in mice injected
with Oct4A KD cells. n = 8 mice per Oct4A knockdown group were maintained over a 6 month period and monitored for tumour development. Mice
were culled and death reported as mice reached predetermined endpoint criteria (Refer to Methods and Materials for list of criteria). Mice injected with
Oct4A KD cells displayed significant increase in mean survival as determined by Kaplan-Meier survival analysis
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lated with vector control cells developed debilitating tu-
mours and required euthanization. In contrast, mice
injected with Oct4A KD1 cells displayed an average survival
period of 125.8 days (4.5-fold increase compared to vector
control mice), while those injected with Oct4A KD2 cells
exhibited a survival period of 61.6 days (2.2-fold increase).
In total, 60 % (5/8) of mice injected with HEY Oct4A KD1
cells and 12.5 % (1/8) of mice injected with HEY Oct4A
KD1 cells failed to produce any evidence of tumour forma-
tion over the 6 month analysis period (experiment end-
point). These results suggest that suppression of Oct4A not
only reduces tumour burden in mice but significantly de-
lays the onset of tumour formation.Oct4A suppression in HEY cells abrogated the invasive
ability of tumour cells to vital organs in in vivo mouse
models
To further evaluate the role of Oct4A in EOC tumour
metastasis, tumour organ infiltration patterns generated
by vector control and Oct4A KD cells 4 weeks post in-
oculation were assessed using H&E staining. In line with
our previous studies [15], mice injected with vector con-
trol cells produced tumours which infiltrated the pan-
creas, liver, kidney, small and large bowels (Fig. 7 &
Additional file 2: Figure S2). While, most of the metasta-
ses located on the lungs, kidneys and bowels were seen
to focally penetrate the respective organ, those located
on the liver were seen to penetrate deep within the
Fig. 7 H&E staining of organ infiltration by vector control, Oct4A KD1 and OCT4A KD2 HEY cells. Representative H&E images of pancreas, liver,
kidney, small and large bowels in mice injected with HEY vector control, Oct4A KD1 and Oct4A KD2 cells (n = 4/mouse group). Images show
vector control cells infiltrating all organs with the exception of the kidneys. Oct4A KD cells do not undergo organ infiltration with tumour
deposits only found within sections of adipose tissue. Arrows indicate tumour cells invading respective organs. Magnification is set at 100x. Scale
bar represents 100 μM
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the pancreas were seen to completely replace the organ.
On the other hand, mice injected with Oct4A KD cells
displayed no evidence of organ infiltration by tumour
cells, with tumour deposits found only in areas of adipose
tissue surrounding the kidney, small and large bowels.
Knockdown of Oct4A significantly reduced the expression
of Oct4, Sox2, CA125, Ki67 and Bcl2 in xenografts derived
from Oct4A KD cells compared to vector control
xenografts
Immunohistochemistry analysis was performed on surgi-
cally excised tumours from mice inoculated with vector
control and Oct4A KD cells. Consistent with monolayer
and spheroid cultures, the expression of Oct4 and Sox2
was significantly reduced in tumours derived from
Oct4A KD cells compared to those derived from vector
control cells (Fig. 8a). The expression of Lin28 was also
markedly reduced in Oct4A KD tumour xenografts,
however this was not statistically significant. Addition-
ally, the expression of Ki67 and Bcl-2 were significantly
reduced in Oct4A KD xenografts and was consistent
with overall reduced tumour size in Oct4A KD xeno-
grafts (Fig. 8b). Immunostaining also revealed that CA125
expression was significantly reduced in Oct4A KD xeno-
graft tumours compared to those derived from vector con-
trol cells. This suggests that the overall tumour formingability of HEY cells in vivo has been suppressed following
loss of Oct4A expression in vitro.
Discussion
Despite extensive treatment regimes, ascites-mediated
recurrence continues to remain a critical process in the
progression of EOC [36]. Understanding the molecular
mechanisms which contribute to the survival of exfoli-
ated primary ovarian tumour cells in the peritoneal cav-
ity therefore remains vital in the management of the
disease. During the past few years, the embryonic tran-
scription factor Oct4 has received considerable attention
in cancer stem cell biology and its expression has been
reported in a wide range of tumours [45]. However, un-
familiarity with the several known Oct4 isoforms, as well
as the existence of a high number of pseudogenes [30] has
led to the misinterpretation of several results surrounding
Oct4A in the context of stem cell biology [30]. A more
rigorous analysis of the specific Oct4 isoforms is therefore
required to elucidate their functional roles in cancer.
Although the expression of Oct4 has previously been
reported in ovarian tumours [46] and patient ascites
samples [47], this is the first study to our knowledge to
demonstrate the expression of the specific Oct4A isoform
in serous ovarian tumours and chemotherapy-treated re-
current serous patient ascites samples. We demonstrate
that Oct4A is significantly elevated in serous borderline
Fig. 8 (See legend on next page.)
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Fig. 8 a Expression of Oct4, Lin28, Sox2, CA125, Ki67 and Bcl-2 in mouse tumour xenografts generated by vector control, Oct4A KD1 and Oct4A
KD2 cells. Representative immunohistochemistry staining images of debulked mouse xenografts for the expression of Oct4, Lin28 and Sox2.
b Representative immunohistochemistry staining images of debulked mouse xenografts for the expression of CA125, Ki67 and Bcl-2. All
images are set at 200x magnification and scale bar represents 50 μM. Quantification of antibody staining was determined by using Image J
software recognizing DAB intensity. Variations in staining were determined by subtracting the negative control DAB reading from the
protein of interest DAB reading for each xenograft. Data is presented as the mean ± SEM of staining intensity (n = 4/group). Significant
variations between Oct4A KD groups and vector control were determined by student’s t-test *p < 0.05; **p < 0.01
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elevated expression is retained throughout the histological
spectrum of serous ovarian tumours. Due to a small sam-
ple size used in the current study, no elucidation between
the elevated expression of Oct4A and patient’s prognosis
could be determined. However, this combined with the
significant elevation of Oct4A expression in the tumour
cells isolated from the ascites of recurrent patients com-
pared to those from chemonaive patients suggests that el-
evated expression of Oct4A may not only have a role in
ovarian cancer progression but may also facilitate recur-
rence. Interestingly and in this context, the Oct4A-
abundant HEY cell line has previously been shown to form
highly robust and aggressive tumours in mouse models
[15]. Alternatively, the Oct4A low expressing OVCA433 is
not tumourigenic in in vivo mouse models [48]. Such ob-
servations may potentially correlate to the proposed CSC-
like functional role of Oct4A in regulating ovarian tumour
growth and survival [35, 49].
The current literature on the functional role of Oct4
in epithelial ovarian cancer is relatively sparse, with the
transcription factor primarily being used as a marker to
detect CSC-like cells in primary ovarian tumours and
patient ascites samples [50]. In this study using shRNA-
mediated knockdown of Oct4A, we provide evidence to
support the concept that the Oct4A isoform may be a
key regulatory factor associated with cancer stem cell-
like properties in serous ovarian tumours. It has previ-
ously been shown that cancer cells cultured as spheroids
exhibit enhanced tumourigenic and metastatic ability
combined with increased expression of CSC-like genes
[36]. Here we demonstrate that knockdown of Oct4A in
HEY ovarian cancer cell line not only significantly dimin-
ishes the anchorage-independent growth of ovarian cancer
cells as spheroids, but results in the decreased expression
of oncogenic and CSC-like Lin28 and Sox-2 expressions
compared to vector control cells. Since both Lin28 and
Sox2 function to maintain self-renewal in pluripotent
stem cell populations [51, 52], this result further empha-
sizes the role of Oct4A as a master regulator of self-
renewal in stem cell-like populations. It is also the first
study to suggest the regulation of Lin28 and Sox2 by the
specific Oct4A splice variant in EOC. The expression of
both EpCAM and CD44 were also significantly reduced in
knockdown cells compared to vector control cells,suggesting that the loss of anchorage independent state as
spheroids in Oct4A knockdown cells may be due to the
loss of cell-cell adhesive molecules such as EpCAM and
CD44. The interaction between CD44 and Oct4 has previ-
ously been described in squamous cell tumours [53], and
EpCAM and CD44 have previously been implicated in
malignant ovarian tumours [54, 55]. However, the associ-
ation between EpCAM and CD44 with regards to the spe-
cific Oct4A isoform remains to be identified. We also
demonstrate that loss of Oct4A expression resulted in a
significant reduction in proliferation and migration of
HEY cells, emphasizing the vital role of Oct4A in tumour
cell survival and migration. Loss of Oct4A expression also
correlated with significantly reduced expression of MMP2
suggesting that the invasive ability of HEY cells has been
reduced following Oct4A knockdown. These observations
were further validated in mouse xenograft experiments
which showed significantly reduced tumour burden,
tumour organ invasion and overall significantly enhanced
survival of mice injected with Oct4A knockdown cells
compared to vector control cells. In addition, tumour xe-
nografts derived from Oct4A knockdown cells displayed
relatively lower abundance of markers associated with
ovarian cancer including oncogenic markers Lin28 and
Sox2, along with proliferation maker Ki67 and anti-
apoptotic Bcl-2 expression. This indicates that reduced
tumourigenic ability, combined with a reduction in prolifer-
ative ability mediated by a loss of Oct4A may have slowed
or abrogated tumour formation and growth. Interestingly,
tumour xenografts generated from Oct4A knockdown
HEY cells exhibited significantly lower CA125 expression.
Elevated levels of CA125 are a hallmark characteristic in
ovarian cancer diagnosis and is frequently observed in re-
lapsed ovarian cancer patients [56] and suggests that the tu-
mours generated by Oct4A knockdown cells are overall less
tumourigenic and aggressive compared to those with abun-
dant Oct4A expression.
Overexpression of Oct4 has previously been implicated
with chemoresistance in tumours [57]. Here we demonstrate
significant elevation of Oct4A expression in established
EOC cells which survived cisplatin treatment. This corre-
lated with significantly elevated expression of Oct4A in
the isolated tumour cells derived from the ascites of che-
moresistant recurrent EOC patients compared to those of
chemonaive patients. This highlights the potential role that
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hibited by tumour cells of EOC patients. Interestingly, this
observation was further reinforced after loss of Oct4A ex-
pression in HEY cells which resulted in the increase in the
sensitivity to cisplatin treatment, suggesting a direct role of
Oct4A in cisplatin-mediated drug resistance which is crit-
ical for ovarian tumour recurrence.
Conclusions
In summary, this study highlights new insights into the
biology of Oct4A in serous ovarian cancer and indicates
that Oct4A plays a crucial role in serous ovarian tumor
progression, survival, chemoresistance and metastasis. It
could therefore be hypothesised that following exfoli-
ation into the peritoneal cavity, Oct4A expressing pri-
mary EOC tumour cells are capable of long termFig. 9 A proposed model of Oct4A-mediated epithelial ovarian recurrence: a
Oct4A-expressing EOC ascites tumour cells. A population of Oct4A-expressing
capable of surviving traditional combination therapy consisting of cisplatin and
of multicellular tumour aggregates (spheroids) or directly 'seed' at a metastati
therapy. Oct4A-expressing primary ovarian tumour cells would still be capable
Oct4A expressing ascites tumour cells would be targeted by Oct4A-specific th
resulting in the inhibition of tumour cell survival and the prevention of ongoisurvival through ongoing self-renewal, tumourigenicity
and chemoresistance which would contribute to the re-
currence of EOC tumours (Fig. 9). We conclude that en-
hanced expression of Oct4A in the ascites-derived
tumour cells can be potentially used as an indicator of
chemoresistance and subsequent for relapse in serous
ovarian cancer patients. Targeting Oct4A through novel
therapeutics may provide an important strategy to over-
come ovarian cancer metastasis and chemoresistance.
Materials and methods
Patient samples
Tissue collection
Primary serous epithelial ovarian tumours and normal
ovarian tissues were obtained from patients requiring
surgical resection after obtaining written informed consentCurrent model of Oct4A mediated recurrence driven by drug resistant
tumour cells which disseminate directly into the peritoneal cavity are
paclitaxel. These cells maintain long term tumourigenicity by the formation
c site to initiate secondary/recurrent disease. b Model of Oct4A targeted
of exfoliating directly into the peritoneal cavity. In contrast however,
erapy (potentially in combination with cisplatin and paclitaxel treatment)
ng cancer progression/recurrence
Table 4 Primer sequences of oligos used in quantitative
Real-Time PCR
Oligo
name
Forward (F) 5’-3’ Primer sequence (5'-3')
Reverse (R) 5’-3’
Oct4A F CTC CTG GAG GGC CAG GAAT C
R CCA CAT CGG CCTG TGT ATA T
Lin28 F CAA AAG GAA AGA GCA TGC AGA AG
R GCA TGA TGA TCT AGA CCT CCA CA
Sox2 F ATG CAC CGC TAC GAC GTG A
R CTT TTG CAC CCC TCC CAT TT
CD44 F CCA ATG CCT TTG ATG GAC CA
R TGT GAG TGT CCA TCT GAT TC
EpCAM F CGT CAA TGC CAG TGT ACT TCA GTT G
R TCC AGT AGG TTC TCA CTC GCT CAG
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Ethics Committee (HREC approval # 09/09) of The
Royal Women’s Hospital, Melbourne, Australia. The histo-
pathological diagnosis, tumour grades and stages were de-
termined by anatomical pathologists at the Royal Women’s
Hospital as part of clinical diagnosis (Tables 1&2). Patients
who were treated with chemotherapy prior to surgery were
excluded from specimen collection. Tissues were paraffin
embedded or snap frozen at the time of collection and
stored at −80 °C until processed.
Ascites collection
Ascites was collected from patients diagnosed with Stages
III-IV ovarian serous cystadenocarcinoma or adenocarcin-
oma Not Otherwise Specified (NOS) after obtaining writ-
ten informed consent under the protocols approved by
the HREC approval #09/09. The histopathological diagno-
sis, tumour grades and stages were determined by ana-
tomical pathologists at the Royal Women’s Hospital as
part of clinical diagnosis (Table 3). Ascites collected from
patients at the time of diagnosis and prior to the com-
mencement of treatment were termed chemonaïve (CN).
Ascites were also collected from patients at the time of re-
currence (CR). Patients in this group had previously re-
ceived different chemotherapy combinations as described
in Table 3. All patients have been classified according to
their survival status as either 'alive' or 'deceased' at the
time of manuscript preparation. Those labeled as 'At Last
Contact (ALC)' were no longer receiving treatment at The
Royal Women's Hospital at the time of manuscript prepar-
ation. Consequently, their current status remains unknown.
Preparation of tumour cells from ascites of ovarian cancer
patients
Tumour cells from ascites were isolated as previously
described [14].
Cell lines and media
Four established human epithelial ovarian cancer cell
lines SKOV3, OVCAR5, OVCA433, and HEY were used
in this study. The growth conditions of these cell lines
have been described previously [58]. The human ovarian
surface epithelial cell line (IOSE398) transfected with the
SV-40 antigen was obtained from Dr Nelly Auersperg,
University of British Columbia, Canada [59]. Cells were
routinely checked for mycoplasma infection.
Antibodies
Monoclonal antibody against human Oct4A and the sec-
ondary anti-mouse IgG HRP antibody was obtained from
R&D Systems (Minneapolis, Minnesota, USA). Monoclonal
and polyclonal antibodies against human Sox2 and Lin28
were obtained from Cell Signalling Technology (Danvers,
Massachusetts, USA). The polyclonal antibody againstGAPDH was obtained from IMGENIX (San Diego, CA,
USA). Secondary anti-rabbit IgG antibody was obtained
from Millipore (Billerica, MA, USA). DAPI Nucleic acid
stain and Alex Fluor® 488 goat anti-mouse IgG were ob-
tained from Life Technologies (Carlsbad, CA, USA).
Immunohistochemistry
Immunohistostaining of primary human tissue specimens
for Oct4A was performed using components from the
CINtek® p16 Histology Kit (Roche) as described by the
manufacturer. Sections were assessed microscopically for
positive DAB staining and quantified using the open
source image processing package Fiji (Fiji Is Just ImageJ)
with a plug-in developed to recognize total DAB stain-
ing. Refer to the Supplementary Method for a detailed
methodology.
RNA extraction and real-time PCR
Quantitative real-time PCR was performed as described
previously [14]. Relative quantification of gene expression
was normalized to 18S and calibrated to the appropriate
control sample using the SYBR Green-based comparative
CT method (2-ΔΔCt). The primer sets for Oct4A Lin28,
Sox2, EpCAM and CD44 are described in Table 4. The
probe for 18S has been described previously [46].
shRNA transfection of HEY ovarian cancer cell line
The HEY-Oct4A shRNA clones (Oct4A KD1 and Oct4A
KD2) were generated by transfecting cells with the
pLKO.1 Mission shRNA custom DNA construct (Sigma-
Aldrich) using FuGENE HD transfection reagent (Roche)
following the manufacturer’s protocol and using Puro-
myocin selection. The target sequence for the Oct4A
construct was based on published genomic sequences of
Oct4A [31] on human chromosome 6 (accession no.
NM_002701) and retrieved from the public databases
at the National Center for Biotechnology Information
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lows: CCTTCGCAAGCCCTCATTTCA. Vector control
HEY cells were generated by stably transfecting a non-
target shRNA negative control.
Western blotting
Cell lysates were extracted using the NU-PER nuclear and
cytoplasmic extraction kit (Thermo Scientific, Waltham,
MA, USA) as per manufacturer's instructions. SDS-PAGE
and Western blot was performed on the cell lysates as de-
scribed previously [13]. All membranes were probed for
48 h with primary Oct4A, Lin28 or Sox2 antibodies set at
1:1000 dilutions.
Spheroid forming assay
The spheroid forming ability of cells was determined by
seeding cells in ultra-low attachment 6 well culture
plates as described previously [13]. Cellular aggregates
with a diameter greater than 200 μm were classified as
spheroids.
Spheroid viability assay
The viability of 18 day spheroids was assessed by directly
seeding spheroids onto 6 well plastic culture plates and
culturing for 24 h at 37 °C in the presence of 5 % CO2.
Adherent spheroids were formalin fixed, stained with
5 % crystal violet and counted manually.
Cell migration assays
The migratory ability of cells was assessed by wound
healing assay as described previously [13]. Quantitative
analysis of cell migration was determined by measuring
the width of the wound at 10 randomly selected points
at t = 0 h and t = 24 h post wound incision using an ocu-
lar micrometer. Migration was expressed as a percentage
of 24 h wound closure compared to 0 h.
Proliferation assays
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium
bromide (MTT) (Sigma-Aldrich) assays were used to
quantify cell proliferation rates as described previously
[45]. Briefly, 4 x 103 cells were seeded in 96-well plates
and cultured at 37 °C in the presence of 5 % CO2 until
required for analysis at 24 h, 48 h and 72 h time points.
On the day of analysis, the growth media was discarded
and MTT (dissolved in 1X PBS solution; final concentra-
tion 0.5 mg/mL in 1 X PBS) was added. Cellular metab-
olism of MTT was permitted to occur at 370 in the
presence of 5 % CO2. Following incubation, the MTT re-
agent was removed, 100 μL of dimethyl sulfoxide
(DMSO) added and cells left to incubate for 10 mins in
to dissolve formazan crystals. Samples were read at
OD595nm using the SpectraMax190 Absorbance Micro-
plate Reader and SoftMax® Pro Computer Software(Molecular Devices). Proliferation rates are expressed as
a percentage of cell growth compared to 24 h.
Chemosensitivity assays
The 50 % growth inhibition (GI50) value for cells in re-
sponse to 72 h cisplatin treatment was performed using
MTT assays as described previously [45]. Briefly, 4 X 104
cells were seeded in 96-well plates in appropriate growth
medium and incubated for 24 h in humidified atmos-
phere at 37 °C in the presence of 5 % CO2. Following
24 h incubation, culture media was removed and
substituted with complete growth media containing in-
creasing concentrations of cisplatin. Cells were subjected
to 72 h cisplatin treatment and the chemosensitivty of
each cell line determined by standard MTT assay as de-
scribed above. Chemosensitivity is expressed as a per-
centage of cell survival at 72 h compared to untreated
control cells.
Animal studies
Animal ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
the Laboratory Animals of the National Health and
Medical Research Council of Australia. The experimen-
tal protocol was approved by the Department of Surgery,
Royal Melbourne Hospital, Australia Animal Ethics
Committee (Project-006/11).
Animal experiments
Animal experiments were performed as described previ-
ously [15]. Metastatic development was documented by
a Royal Women's Hospital pathologist according to
histological examination (H&E staining) of the organs as
described previously [20].
Immunohistochemistry of mouse tumours
Immunohistochemistry analysis of mouse tumours was per-
formed as described previously [20]. Primary antibodies
against human Oct4, Lin28, Sox2, Ki67, Bcl-2 and CA-125
were diluted according to the manufacturer's instruction.
Primary antibody staining was detected using the ultraView
Universal DAB detection kit (Roche). Negative controls
were prepared for each section throughout the staining
process by incubating tumour xenografts in the absence of
primary antibodies. Images of immunohistochemical stain-
ing were taken using an Aperio ImageScope (Leica Micro-
systems, Mt Waverly, Australia) and associated digital
pathology viewing software. DAB staining was measured by
taking a minimum of 10 images per tumour section and
running the images through the open source image pro-
cessing package Fiji (Fiji Is Just ImageJ) with a plug-in de-
veloped to recognise DAB staining.
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All results are presented as the mean ± standard error of
the mean (SEM) of three independent experiments. Stat-
istical significance was measured compared to the vector
control using one way-ANOVA and Dunnett’s Multiple
Comparison test unless otherwise indicated. A probabil-
ity level of <0.05 was adopted throughout to determine
statistical significance.
Additional files
Additional file 1: Figure S1. Evidence of Oct4A expression and
localization in additional primary serous epithelial ovarian tumour
samples. Immunohistochemical staining of Oct4A in normal ovary,
borderline, grade 2 and grade 3 primary ovarian tumours. Positive Oct4A
expression is indicated by intense nuclear staining. Images are set at
200x. Scale bars represent 10 μM. (JPEG 58 kb)
Additional file 2: Figure S2. H&E staining of organ infiltration by vector
control, Oct4A KD1 and OCT4A KD2 HEY cells (200x magnification).
Representative H&E images of pancreas, liver, kidney, small and large bowels
in mice injected with vector control, Oct4A KD1 and Oct4A KD2 cells (n= 4/
mouse group). Images show vector control cells infiltrating all organs with the
exception of the kidneys. Oct4A KD cells do not undergo organ infiltration
with tumour deposits only found within sections of adipose tissue. Arrows
indicate tumour cells invading respective organs. Magnification is set at 200x.
Scale bar represents 100 μM. (JPEG 80 kb)
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